Jacobs Levy Equity Management, Inc Allovir, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Allovir, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 664,423 shares of ALVR stock, worth $6.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
664,423Holding current value
$6.36 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALVR
# of Institutions
49Shares Held
21.1MCall Options Held
41KPut Options Held
100-
Siren, L.L.C. New York, NY6.6MShares$63.1 Million0.12% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$29 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$25.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.91MShares$18.3 Million0.06% of portfolio
-
Black Rock Inc. New York, NY634KShares$6.07 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $891M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...